Recursion Pharmaceuticals (RXRX) Projected to Post Earnings on Tuesday

Recursion Pharmaceuticals (NASDAQ:RXRX) is anticipated to announce its earnings data before the market opens on Tuesday, February 25th. Analysts expect the company to announce earnings of ($0.44) per share and revenue of $19.04 million for the quarter.

Recursion Pharmaceuticals Trading Up 23.9 %

NASDAQ:RXRX opened at $10.53 on Tuesday. Recursion Pharmaceuticals has a 52 week low of $5.60 and a 52 week high of $15.74. The firm has a 50-day moving average price of $7.32 and a two-hundred day moving average price of $6.93. The company has a debt-to-equity ratio of 0.04, a quick ratio of 4.35 and a current ratio of 4.35. The firm has a market cap of $4.11 billion, a price-to-earnings ratio of -6.88 and a beta of 0.86.

Analyst Ratings Changes

RXRX has been the topic of a number of recent analyst reports. KeyCorp dropped their price target on Recursion Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating on the stock in a report on Wednesday, January 8th. Needham & Company LLC reiterated a “buy” rating and set a $11.00 target price on shares of Recursion Pharmaceuticals in a research note on Thursday, February 6th.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.